Most important take away

Earnings season delivered solid core results from Uber, Disney, and Novo Nordisk, but each story is fundamentally about strategic transitions and skepticism on follow-through. Uber’s “everything app” ambitions face stiff consumer-behavior headwinds even as core ride share grows 14%; Disney is showing it can be steady, profitable ballast under new CEO Josh D’Amaro; Novo Nordisk is trading margins for volume in a price war it may be losing to Eli Lilly.

Summary

Actionable insights and stocks discussed:

Uber (UBER) - Shares were up ~10% on the day, down ~12% over the past year. Revenue grew 14%, gross bookings up 25%. Core ride sharing and delivery business looks strong. Uber is pushing toward a “super app” strategy by adding hotels (via Expedia), vacation rentals (Vrbo), and bundling rides with travel through Uber One.

• Lou Whiteman is skeptical: every “everything app” attempt (PayPal, Meta/WhatsApp, Airbnb experiences) has failed in Western markets because consumer behavior is hard to change. Travelers already use booking.com, Delta, Capital One travel, etc.
• Rachel Warren is more open: super-app models work in Asia (WeChat, Grab, Gojek) and the Uber One subscription could create a Costco-like loyalty loop.
• Actionable insight: invest in Uber for the core business growth and compounding, not the everything-app narrative. Treat hotel/travel additions as optional upside; do not pay a premium for them.

Disney (DIS) - Shares up ~8% on earnings. Record $25B revenue (+7% YoY), Disney+/Hulu operating income up 88%, entertainment revenue up 10%, experiences up 7% with higher per-guest spend. Trades at ~17x trailing / under 15x forward earnings.

• Strategy: new CEO Josh D’Amaro (only 14 days in role for the quarter) is centralizing marketing, using AI personalization to keep streaming margins above 10%, executing strategic layoffs, and continuing the $60B investment plan in parks/experiences.
• Bullish thesis: the experiences segment (parks, cruises, Florida capacity expansion) is a safer long-term bet than competing in the Netflix content arms race. IP gets monetized multiple times.
• Bearish/cautious thesis (Lou): the conglomerate structure (legacy TV, sports, streaming, parks) drags on returns. Disney could benefit from divestitures or partnerships in sports and streaming to focus on parks/IP.
• Actionable insight: Disney looks like “ballast” - mid-teens P/E, single-digit growth, defensive in a market pullback (unless that pullback is consumer-driven, which would hit parks). Reasonable long-term hold for value-oriented investors.

Novo Nordisk (NVO) - Stock down ~75% from 2024 peak; shares bounced on this report.

• The oral Wegovy pill did $354M in its first full US quarter, roughly double analyst expectations, and Wegovy controls ~65% of new US obesity prescriptions. Overall sales up 32% constant currency. Guidance for the contraction was raised (now -4% to -12% vs prior -13%).
• Concerns: Novo is cutting prices up to 70% in some channels, with list prices set to drop another 50% in 2027. The oral pill needs more semaglutide per dose than injections, hurting margins. Massive capex on factories in Ireland and Italy could become underutilized. US patent expires in ~5 years; Canadian exclusivity was lost due to a paperwork error.
• Competitive threat: Eli Lilly (LLY) is investing heavily in next-gen GLP-1s (e.g., retatrutide) and non-GLP-1 pipeline assets, while Novo’s pipeline is mostly GLP-1 variants.
• Actionable insight: caution on Novo Nordisk despite the bounce - this is a “make it up on volume” story with shrinking margins. Eli Lilly looks like the stronger long-term bet in the GLP-1 / obesity space. Watch for Novo to redeploy profits into a more diversified pipeline before adding exposure.

Disclaimer noted: hosts may own positions; The Motley Fool may have formal recommendations. Do not buy or sell solely based on the discussion.

Chapter Summaries

Uber’s Everything-App Bet (intro to first break) - Hosts debate Uber’s strategy shift from ride hailing into a super app spanning hotels (Expedia), vacation rentals (Vrbo), and bundled travel via Uber One. Core business grew 14% revenue, 25% gross bookings. Lou is bearish on the everything-app thesis citing failed precedents (PayPal, WhatsApp, Airbnb experiences) and entrenched consumer habits. Rachel cites Asian super-app success (WeChat, Grab, Gojek) and a potential Costco-style subscription loyalty loop. Shares popped 10%.

Disney’s Steady Quarter (middle segment) - First quarter under new CEO Josh D’Amaro (only 14 days at helm). Record $25B revenue up 7%, Disney+/Hulu operating income up 88%, experiences up 7% with higher per-guest spend. Discussion centers on whether Disney’s conglomerate structure (legacy TV, sports, streaming, parks) holds it back, and whether D’Amaro will pursue divestitures. Trades at 17x trailing / sub-15x forward earnings - a defensive “ballast” stock. Shares up 8%.

Novo Nordisk’s Volume Play (final segment) - Oral Wegovy pill exceeded expectations at $354M in its first US quarter; Wegovy holds 65% of new US obesity prescriptions. But Novo is slashing prices up to 70%, the oral pill consumes more semaglutide (margin drag), and massive factory capex risks underutilization. Eli Lilly is pulling ahead with a more diversified pipeline. US patent expires in 5 years; Canadian exclusivity lost via paperwork failure. Verdict: cautious - looks like a one-trick pony chasing volume.